Large gap with delayed quotes
|
Last quote
12/27/2024 -
20:00:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
6.01
+0.01
(
+0.17% )
|
6.01
|
4,600 |
6.04
|
600 |
Analysis date: 24.12.2024
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 13.12.2024.
Interest
Very weak
Very weak
Very weak interest since 26.11.2024.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 26.11.2024 at a price of 8.56.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, at its current price the stock is strongly overvalued.
MT Tech Trend
Negative
Negative
The forty day Medium Term Technical Trend is negative since 29.10.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is
4wk Rel Perf
-33.18%
-33.18%
The four week relative underperformance versus SP500 is 33.18%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 13.12.2024.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.63%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 5.70%.
Mkt Cap in $bn
0.14
0.14
With a market capitalization <$2bn, ENANTA PHARMACEUTICALS is considered a small-cap stock.
G/PE Ratio
4.71
4.71
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
-1.69
-1.69
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
7.95%
7.95%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
6
6
Over the last seven weeks, an average of 6 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
75
75
For 1% of index variation, the stock varies on average by 0.75%.
Correlation
0.15
0.15
Stock movements are totally independent of index variations.
Value at Risk
1.46
1.46
The value at risk is estimated at USD 1.46. The risk is therefore 24.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
19.09.2014
19.09.2014